



Cardiovascular

Fall 2017 Cycle

CSAC Review and Endorsement

June 4, 2018

Cardiovascular

- Cardiovascular disease (CVD) is the leading cause of death for men and women in the United States
- CVD kills nearly one in four Americans and costs \$312 billion per year, more than 10 percent of annual health expenditures¹
- Measures that assess clinical care performance and patient outcomes are critical to reducing the negative impacts of CVD.
- Cardiovascular portfolio of measures is one of the largest (e.g., primary prevention and screening, coronary artery disease (CAD), ischemic vascular disease (IVD), acute myocardial infarction (AMI), etc.)
- Gaps remain in patient-reported outcomes and patient-centric composite measures

1 Agency for Healthcare Research and Quality (AHRQ). *2015 National Healthcare Quality and Disparities Report and 5th Anniversary Update on the National Quality Strategy*. Rockville, MD: AHRQ; 2016.
<http://www.ahrq.gov/research/findings/nhqdr/nhqdr15/index.html>. Last accessed March 2018.

Cardiovascular Measures Under Review

- The Committee evaluated four measures undergoing maintenance review and one newly submitted measure in the following topic areas (some measures addressed more than one topic area):
 - *Acute Myocardial Infarction (AMI)*
 - *Cardiac Surgery*
 - *Cardiac Rehabilitation*
 - *Coronary Artery Disease*
 - *Percutaneous Coronary Intervention (PCI)*
 - *In-Hospital Cardiac Arrest*

Cardiovascular Standing Committee Recommendations

- Initially, the Committee recommended four measures for endorsement, and did not reach consensus (CNR) on measure 3309 *Risk-Standardized Survival Rate (RSSR) for In-Hospital Cardiac Arrest*.
- During the post-comment call, the developer withdrew the CNR measure from endorsement consideration.

Recommended Measures

- Recommended measures:
 - *Percutaneous Coronary Intervention (PCI) – 2 measures*
 - » Types of measures: 0 process; 0 composite; 2 outcome
 - *Cardiac Rehabilitation – 2 measures*
 - » Types of measures: 2 process; 0 composite; 0 outcome

Measure Evaluation Summary

	Maintenance Measures	New Measures	TOTAL Measures
Submitted	4	1	5
Measures Recommended	4	0	4
Measures Not Recommended	0	0	0
Measures Withdrawn from Consideration	0	1	1
Reasons for not recommending:	Importance – 0 Scientific Acceptability – 0 Overall – 0	Importance – 0 Scientific Acceptability – 0 Overall – 0	

Public and NQF Member Comments Received

- NQF received 11 comments from three member organizations.
- Measure-specific comments: NQF received 10 post-evaluation comments in support for recommending the new measure 3309.
 - *Note: Due to the Committee's concerns with the inaccuracies of the data presented in the revised testing document for measure 3309, the developer withdrew the measure. The developer intends to resubmit the measure in a future cycle.*

Member Expression of Support

Two NQF members expressed their support.

- Both NQF members (health professional and provider organization) expressed their support for measure 3309: *Risk-Standardized Survival Rate (RSSR) for In-Hospital Cardiac Arrest*
- One NQF member (provider organization) expressed support for measure 0642 *Cardiac Rehabilitation Patient Referral From an Inpatient Setting*

CSAC Checklist

Key Considerations	Yes/No	Notes
Were there any process concerns raised during the CDP project? If so, briefly explain.	Yes	The Committee raised concerns with the accuracy of data found in the reliability and validity testing results included in the testing attachment presented by the developer for the reliability of 3309 <i>RSSR for In-Hospital Cardiac Arrest</i> ; furthermore, this was a concern that was not flagged by the Methods Panel.
Did the Standing Committee receive requests for reconsideration? If so, briefly explain.	No	
Did the Standing Committee overturn any of the Scientific Methods Panel's ratings of Scientific Acceptability? If so, state the measure and why the measure was overturned.	Yes	The Committee did not reach consensus on the reliability of 3309 due to inaccuracies in the data presented in the testing document. The developer submitted a revised testing document during the commenting period. On the post-comment call, the Committee found additional inaccuracies in the data presented in the revised testing document. The developer withdrew the measure from consideration for endorsement prior to the Committee's vote on endorsement consideration.

CSAC Checklist

Key Considerations	Yes/No	Notes
If a recommended measure is a related and/or competing measure, was a rationale provided for the Standing Committee's recommendation? If not, briefly explain.	No	
Were any measurement gap areas addressed? If so, identify the areas.	No	
Are there additional concerns that require CSAC discussion? If so, briefly explain.	No	

Timeline and Next Steps

Process Step	Timeline
Appeals Period	June 7, 2018-July 6, 2018
Adjudication of Appeals	July 9, 2018-August 3, 2018
Final Report	September 2018

Questions?

- Project webpage: [http://www.qualityforum.org/Project Pages/Cardiovascular.aspx](http://www.qualityforum.org/Project_Pages/Cardiovascular.aspx)
- Project email address: cardiovascular@qualityforum.org